secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aardvark Therapeutics, Inc. (AARD)
CIK:        0001774857
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0000950170-25-108082
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aardvark Therapeutics Q2 net loss $14.4M; advances ARD-201 obesity trials and expands PWS trial to younger patients
--------------------------------------------------------------------------------

- Net loss of $14.4M in Q2 2025 vs $5.4M in Q2 2024; R&D expenses rose to $13.1M.
- Cash, cash equivalents, and short-term investments of $141.8M as of June 30, 2025; funds operations into 2027.
- Preclinical data shows ARD-201 prevents weight regain after GLP-1RA discontinuation; Phase 2 POWER trial in H2 2025, STRENGTH in H1 2026.
- Phase 3 HERO trial for ARD-101 in PWS to expand to patients under 13; topline data expected Q3 2026.
- Appointed new CSO, CCO, SVP Regulatory, and General Counsel in May 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1774857/000095017025108082/0000950170-25-108082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1774857/000095017025108082/ck0001774857-20250813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-108082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer